Clinical trial
Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia
NCT00234481 · Exelixis, Industry · Terminated
Key facts
| NCT number | NCT00234481 |
|---|---|
| Title | Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia |
| Official title | A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL844 Administered Orally to Subjects With Chronic Lymphocytic Leukemia |
| Lead sponsor | Exelixis, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma |
| Intervention type | Drug |
| Interventions | XL844 |
| First posted | Oct 7, 2005 |
| Last update posted | Jun 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: